- Home
- ACIU vs TNYA Comparison
ACIU vs TNYA Comparison
Compare ACIU & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TNYA
- Stock Information
- Founded
- ACIU 2003
- TNYA 2016
- Country
- ACIU Switzerland
- TNYA United States
- Employees
- ACIU N/A
- TNYA N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- ACIU Health Care
- TNYA Health Care
- Exchange
- ACIU Nasdaq
- TNYA Nasdaq
- Market Cap
- ACIU 213.3M
- TNYA 189.1M
- IPO Year
- ACIU 2016
- TNYA 2021
- Fundamental
- Price
- ACIU $2.48
- TNYA $1.20
- Analyst Decision
- ACIU Strong Buy
- TNYA Strong Buy
- Analyst Count
- ACIU 2
- TNYA 5
- Target Price
- ACIU $10.00
- TNYA $8.60
- AVG Volume (30 Days)
- ACIU 132.0K
- TNYA 4.3M
- Earning Date
- ACIU 11-04-2025
- TNYA 11-05-2025
- Dividend Yield
- ACIU N/A
- TNYA N/A
- EPS Growth
- ACIU N/A
- TNYA N/A
- EPS
- ACIU N/A
- TNYA N/A
- Revenue
- ACIU $36,362,036.00
- TNYA N/A
- Revenue This Year
- ACIU N/A
- TNYA N/A
- Revenue Next Year
- ACIU $1,022.98
- TNYA N/A
- P/E Ratio
- ACIU N/A
- TNYA N/A
- Revenue Growth
- ACIU 86.71
- TNYA N/A
- 52 Week Low
- ACIU $1.43
- TNYA $0.36
- 52 Week High
- ACIU $3.98
- TNYA $4.01
- Technical
- Relative Strength Index (RSI)
- ACIU 64.11
- TNYA 56.61
- Support Level
- ACIU $2.12
- TNYA $1.25
- Resistance Level
- ACIU $2.35
- TNYA $1.43
- Average True Range (ATR)
- ACIU 0.13
- TNYA 0.10
- MACD
- ACIU 0.04
- TNYA -0.01
- Stochastic Oscillator
- ACIU 95.74
- TNYA 39.47
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.